Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid-binding Ig-like lectin 28, pseudogene" is a genomic element annotated as a pseudogene and is not known to encode a functional protein product. It is related by sequence homology to the Siglec (Sialic acid-binding immunoglobulin-type lectin) family, which are involved in sialic acid recognition and immune regulation, but this specific gene (ENSG00000269130) is cataloged as a pseudogene, and there is no evidence for peptide expression, therapeutic targeting, or disease relevance[1]. The presence of "pseudogene" in its canonical name and major database entries confirms its noncoding and non-target status. No disease association, biomarker utility, or pharmacological interaction has been reported or predicted. This target is therefore best categorized as a non-target, and its inclusion in therapeutic or biomarker pipelines would be in error.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid-binding Ig-like lectin 28, pseudogene.